RANI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rani Therapeutics Holdings Inc (RANI) is not a strong buy for a beginner, long-term investor at this time. While the company has shown revenue growth and initiated a promising clinical trial, the lack of significant positive trading signals, neutral insider and hedge fund sentiment, and weak financial performance metrics such as negative net income and declining EPS suggest a cautious approach. Additionally, there are no recent news catalysts or influential figure trades to drive immediate interest.
The MACD is positive but contracting, indicating a weakening bullish momentum. RSI is neutral at 50.185, and moving averages are converging, showing no clear trend. Key resistance levels are at 1.016 and 1.096, with support at 0.756 and 0.676. The pre-market price is slightly above the pivot level at 0.946, reflecting mild upward movement.
The company has initiated a Phase I clinical trial for RT-114, which could be a long-term growth driver.
EPS dropped significantly by -74.07% YoY. Net income remains negative at -$10.3M. Analysts have lowered the price target from $9 to $5, reflecting reduced expectations. No recent news or significant trading activity from insiders, hedge funds, or influential figures.
In Q4 2025, revenue increased to $1.46M (up 42.12% YoY), but net income remains negative at -$10.3M (up 15.18% YoY). EPS dropped to -0.07 (down -74.07% YoY), and gross margin remains unchanged at 100%.
Canaccord maintains a Buy rating but has lowered the price target to $5 from $9, citing updated financial results and business highlights. The firm anticipates data from the Phase I trial in 2H26.
